Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] SK hynix (000660) – Additional Listing (Capital Increase (DR)) / 2026-07-24

Posted on July 24, 2026July 29, 2026 By K-STOCK Editor No Comments on [Disclosure] SK hynix (000660) – Additional Listing (Capital Increase (DR)) / 2026-07-24

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

17,790,000 newly issued common shares of SK Hynix, issued through a capital increase via Depositary Receipts (DR), will be additionally listed on the domestic stock market.

📊 [Key Summary & Financial Figures]

  • Company Name: SK Hynix Inc.
  • Stock Code: 000660
  • Share Type & Quantity: Registered Common Shares 17,790,000 shares (45th issue)
  • Issue Price per Share: KRW 2,242,301 (Par Value: KRW 5,000)
  • Capital Increase Method: Capital Increase (DR)
  • Issue Date: July 15, 2026
  • Listing Date: July 29, 2026
  • Dividend Base Date: January 01, 2026 (Fiscal Year End: December 31)

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verifying Changes in Total Issued Shares Following Additional Listing

This disclosure specifies the listing schedule for new shares issued through a capital increase (DR). Verifying how the company’s total number of issued shares has changed following this additional listing is important to understand the actual change in remaining total shares. Relevant details can be checked in subsequent periodic reports (Quarterly, Half-Year, or Annual Reports).

📢 Disclaimer and Source Notice

Source: This content was structured and generated based on official submission data from the Financial Supervisory Service’s DART system.

Investment Risk Notice: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Semiconductors

Post navigation

Previous Post: [Disclosure] Celltrion (068270) – CT-P55 (Cosentyx Biosimilar) Europe Marketing Authorization Application / 2026-07-24
Next Post: [Disclosure] Hanwha Ocean (042660) – Operational Status of Compliance Program (Informational Disclosure) / 2026-07-27

Related Posts

[Disclosure] Daeduck Electronics (353200) – Other Management Matters (Voluntary Disclosure) (Information on Dividend Record Date) / 2025-12-11 Semiconductors
[Disclosure] HPSP (403870) – Change of Chief Executive Officer / 2026-06-25 Semiconductors
[Disclosure] Hanwha Aerospace (012450) to Host Investor Relations (IR) Event for Overseas Institutional Investors in London Starting June 2, 2025 Disclosures
[Disclosure] Hanwha Ocean (042660) – Investor Relations (IR) Announcement (Informational Disclosure) / 2026-05-07 Disclosures
[Disclosure] Celltrion (068270) – Marketing Authorization Granted by South Korean MFDS for Eydenzelt (CT-P42, Eylea Biosimilar) / 2024-05-30 Disclosures
[Disclosure] Celltrion (068270) – Treasury Share Acquisition Decision / 2025-03-21 Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme